Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiomyopeptidin for Myocardium Protection in STEMI Patients Undergoing Primary PCI
NCT06155110Phase 4Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2019
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of cardiomyopeptidin in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Myocardial infarct size according to MR delayed enhancement scan. Started Nov 2019; status: completed.
02
Drugs
cardiomyopeptidin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06155110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155110.